Health · Public Health & Disease · 5 hrs ago
Brazil approves Capvaxive vaccine for adults against 21 pneumococcal types
Brazil’s health regulator, Anvisa, approved the Capvaxive vaccine in late September.
Made by Merck Sharp & Dohme, it is approved for adults aged 18 and older and protects against 21 types of pneumococcus.
This bacterium can cause illnesses ranging from ear and sinus infections to pneumonia, meningitis and sepsis.
It can spread between people through respiratory droplets, and children, older adults and people with weakened immune systems are among those at greater risk.
Anvisa based its decision on six studies involving about 8,400 adults, which assessed the immune response to the vaccine.
There is no date yet for clinic availability or SUS coverage, and a doctor should advise who should receive it and when.
Brazil’s health regulator approved Capvaxive, a vaccine that protects against 21 pneumococcal types.
The vaccine is indicated for adults aged 18 and older and is made by Merck Sharp & Dohme.
There is no confirmed date for its arrival at clinics or its availability through Brazil’s public health system.
The approval followed a review of six phase 3 clinical studies involving about 8,400 adults.
Pneumococcus can cause illnesses including pneumonia, meningitis and sepsis.
- Who
- Brazil’s National Health Surveillance Agency (Anvisa) approved the vaccine.
- What
- Capvaxive was approved to protect against 21 pneumococcal types. It is indicated for adults aged 18 and older.
- When
- Anvisa approved it at the end of September. The article was published on October 19, 2026.
- Where
- Brazil.
- Why
- The vaccine is intended to protect against pneumococcal disease, which can include pneumonia, meningitis and sepsis.
This story does not have two clearly opposing sides.
Anvisa assessed six phase 3 clinical studies conducted across the Americas, Europe, Asia-Pacific and Africa.
Anvisa approved Capvaxive for adults aged 18 and older.
- Vaccine
- Capvaxive
- Coverage
- 21 pneumococcal types
- Approved age
- Adults aged 18 and older
- Manufacturer
- Merck Sharp & Dohme
- Clinical evidence
- Six phase 3 studies involving about 8,400 adults
What people are saying
antibodies of high affinity, development of immune memory and long-lasting protection